Prostatype Genomics AB (PROGEN) Fair Value & Analysis
Healthcare · SE · Market cap 36.9M SEK (≈ $3.8M) · ISIN SE0014684569
Risks
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 45 days ago
Share price −8.6% over the past month.
Below-average quality, and trading another 60% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 0.1445). The favourable scenario is already priced in.
- Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.0765 to kr 0.1445) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range kr 0.0970 – kr 1,757 · fair‑value band kr 0.0765 – kr 0.1445 · the kr 0.1495 price screens above the kr 0.0935 fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Prostatype Genomics AB (PROGEN) currently trades at kr 0.1495, while our model-based Fair Value estimate is kr 0.0935, implying the stock looks roughly 37.5% overvalued today. The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 594K SEK. Revenue declined 26.0% year over year. The balance sheet holds a net cash position of 3.8M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 0.0765 (bear case) to kr 0.1445 (bull case); at kr 0.1495, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -37%, PROGEN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when PROGEN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 25 · Market factors (momentum, volatility) 4
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score.
Full company description
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Prostatype Genomics AB reported revenue of kr 594K in FY2025 versus kr 10.0K in FY2021, a compound +177.6%/yr. Reported net income was −kr 44.5M in FY2025.
PROGEN screens 37% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 140 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | -51% |
| Danaher Corporation DHR | $215.68 | $103.88 | -52% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 587.80 | CHF 259.80 | -56% |
| IDEXX Laboratories, Inc IDXX | $553.44 | $255.77 | -54% |
| Agilent Technologies, Inc A | $155.08 | $61.53 | -60% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $224.84 | $95.51 | -58% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare Prostatype Genomics AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Prostatype Genomics AB (PROGEN) overvalued or undervalued?
What is the fair value of PROGEN?
What is the quality score of PROGEN?
What is the revenue of Prostatype Genomics AB (PROGEN)?
What is the net profit margin of PROGEN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Prostatype Genomics AB in the live analysis
One click puts Prostatype Genomics AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.